← Y-mAbs Therapeutics, Inc. (YMAB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Y-mAbs Therapeutics, Inc. (YMAB)
Pharmaceutical Preparations · market cap $391M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
8
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Y-mAbs Therapeutics (YMAB) is a commercial-stage pharma focused on antibody-based therapies, with its lead asset being GM-CSF combined with naxitamab in Phase 2 for neuroblastoma. The company reported $88M in 2024 revenue against a $30M net loss, suggesting a product already generating meaningful sales. At a $391M market cap and ~$8.61/share, the stock trades at roughly 4.4x trailing revenue with no analyst coverage and no near-term catalysts on the calendar.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Hu3F8 With GM-CSFimp 7/10
- 2027-07-15 (est.)Phase 2 · humanized anti-GD2 antibodyimp 7/10
- 2027-07-15 (est.)Phase 2 · 131 I-omburtamabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GM-CSF + Naxitamab | Phase 2 | Neuroblastoma |
| Hu3F8 With GM-CSF | Phase 2 | Neuroblastoma |
| adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH | Phase 2 | Neuroblastoma |
| Hu3F8 | Phase 2 | Neuroblastoma |
| Naxitamab | Phase 2 | Neuroblastoma |
| 131 I-omburtamab | Phase 2 | Desmoplastic Small Round Cell Tumor |
| humanized anti-GD2 antibody | Phase 2 | Recurrent Osteosarcoma |
| Omburtamab I-131 | Phase 2 | Recurrent Medulloblastoma |
Price & technical context
3-month
+82.8%
6-month
+84.4%
12-month
-35.1%
52-wk range
$3.64–$15.69
vs 50-day MA
+25.8%
vs 200-day MA
+40.7%
Realized vol
95.3%
Max drawdown
-80.5%
Daily closes through 2025-09-15. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for YMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.